How Far Can Big Pharma Collaboration Go? Much Further, Executives Say
This article was originally published in The Pink Sheet Daily
Big pharma collaborations and other new or once-rare models of business development can help companies ‘do more with less’, according to AstraZeneca’s and Merck’s heads of business development, who spoke at Elsevier’s Pharmaceutical Strategic Alliances conference.
You may also be interested in...
AstraZeneca was the top in-licenser, snagging a $3.4 billion pact with BMS for Amylin’s diabetes assets, making metabolic diseases the leading therapeutic area in biopharma alliances.
A baker’s dozen stories from the past year that captured reader interest and reflected biopharma trends.
Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.